What Is Claimed Is:

1. An agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof.

5

- 2. The agent according to claim 1, wherein the hepatic disease is hepatic cancer.
- 3. The agent according to claim 2, wherein the hepatic 10 cancer is des- γ -carboxy prothrombin positive hepatic cancer.
 - 4. The agent according to any one of claims 1 through 3, wherein the agent improves prognosis after hepatic cancer treatment.
- 15 5. The agent according to claim 4, wherein the agent is an agent that inhibits occurrence of portal venous invasion.
 - 6. An agent for inhibiting occurrence of portal venous invasion containing menatetrenone as an active ingredient thereof.

20

- 7. An agent for improving survival rate after hepatic cancer treatment containing menatetrenone as an active ingredient thereof.
- 8. An agent for inhibiting recurrence of hepatocellular carcinoma containing menatetrenone as an active ingredient thereof.

- 9. An agent for reducing des-γ-carboxy prothrombin level containing menatetrenone as an active ingredient thereof.
- 10. A method of preventing portal venous invasion,
 5 comprising administering to a patient an effective dose of a medicine containing menatetrenone as an active ingredient thereof.
 - 11. A method of inhibiting recurrence of hepatocellular carcinoma, comprising administering to a patient an effective dose of a medicine containing menatetrenone as an active ingredient thereof.

10

15

20

- 12. A method of modulating the level of des- γ -carboxy prothrombin in the blood of a patient, comprising administering to the patient an effective dose of a medicine containing menatetrenone as an active ingredient thereof.
- 13. A use of menatetrenone for manufacturing an agent for inhibiting occurrence of portal venous invasion.
- 14. A use of menatetrenone for inhibiting recurrence of hepatocellular carcinoma.
- 15. An agent for treating or preventing hepatic disease containing a vitamin K as an active ingredient thereof.